トリアムテレン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

トリアムテレン 価格

MSDS Information

• 2,4,7-Triamino-6-phenylpteridine

トリアムテレン 化学特性,用途語,生産方法

• 解説

  トリアムテレン，2,4,7-triamino-6-phenylpteridine．C12H11N7(253.26)．2,4,6-トリアミノ-5-ニトロソピリミジンとフェニルアセトニトリルとを反応させると得られる．黄色の結晶．融点316 ℃．λmax 356 nm(ε 21000)．鉱酸に易溶，水，有機溶媒にほとんど不溶．副腎皮質鉱質コルチコイドのアルドステロンにきっ抗して，利用作用を現す．利尿剤，降圧剤，むくみ治療剤に使用される．LD50 410 mg/kg(マウス，経口)．

• 効能

  利尿薬, アルドステロン拮抗薬, 上皮性ナトリムチャネル遮断薬

• 商品名

  トリテレン (京都薬品工業)

• 説明

  Triamterene is an inhibitor of the epithelial sodium channel (ENaC; IC₅₀ = 4.5 μM for the rat channel). In vivo, triamterene (0.5-32 mg/animal) enhances sodium secretion and decreases potassium secretion in adrenalectomized rats. Formulations containing triamterene have been used in the treatment of edema. This product is also available as an analytical reference standard .

• 化学的特性

  Yellow Solid

• 使用

  Triamterene is a potassium-sparing diuretic ie, it inhibits the urinary excretion of potassium

• 生物学の機能

  Triamterene (Dyrenium) results in changes in urinary electrolyte patterns that are qualitatively similar to those produced by spironolactone. The mechanism by which this agents bring about the alterations in electrolyte loss, however, is quite different. Triamterene produces this effects whether or not aldosterone or any other mineralocorticoid is present. The action of this drug is clearly unrelated to endogenous mineralocorticoid activity, and this drug is effective in adrenalectomized patients.

• 一般的な説明

  Odorless yellow powder or crystalline solid. Melting point 316°C. Almost tasteless at first and with a slightly bitter aftertaste. Acidified solutions give a blue fluorescence. Used as a diuretic drug.

• 空気と水の反応

  Sensitive to light; slowly oxidized upon exposure to air. Insoluble in water.

• 反応プロフィール

  2,4,7-Triamino-6-phenylpteridine neutralizes acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen may be generated in combination with strong reducing agents, such as hydrides.

• 火災危険

  Flash point data for 2,4,7-Triamino-6-phenylpteridine are not available; however, 2,4,7-Triamino-6-phenylpteridine is probably combustible.

• 作用機序

  Triamterene is a pyrazine derivative that inhibits reabsorption of sodium ions without increasing excretion of potassium ions. It exhibits the same approximate effect as spironolactone; however, it does not competitively bind with aldosterone receptors. Its action does not have an effect on secretion of aldosterone or its antagonists, which are a result of direct action on renal tubules.
  This potassium sparing diuretic causes a moderate increase in excretion of sodium and bicarbonate ions in urine, and it raises excretion of potassium and ammonia ions. It has little effect on urine volume.

• 臨床応用

  Triamterene can be used in the treatment of congestive heart failure, cirrhosis, and the edema caused by secondary hyperaldosteronism. It is frequently used in combination with other diuretics except spironolactone. Amiloride, but not triamterene, possesses antihypertensive effects that can add to those of the thiazides. These K⁺-sparing diuretics have low efficacy when used alone, since only a small amount of total Na reabsorption occurs at more distal sites of the nephron.
  These compounds are used primarily in combination with other diuretics, such as the thiazides and loop diuretics, to prevent or correct hypokalemia. The availability of fixed-dose mixtures of thiazides with nonsteroidal K⁺-sparing compounds has proved a rational form of drug therapy. Both triamterene and amiloride are available alone or in combination with hydrochlorothiazide.

• 副作用

  Because the actions of triamterene and amiloride are independent of plasma aldosterone levels, their prolonged administration is likely to result in hyperkalemia. Both amiloride and triamterene are contraindicated in patients with hyperkalemia.Triamterene should not be given to patients with impaired renal function. Potassium intake must be reduced, especially in outpatients.A folic acid deficiency has been reported to occur occasionally following the use of triamterene.

トリアムテレン 上流と下流の製品情報

トリアムテレン 生産企業

Global(213)Suppliers

トリアムテレン スペクトルデータ(IR1、IR2、MS、Raman)

396-01-0, トリアムテレン キーワード